Quince Therapeutics, Inc. Market Cap ($30.87 Million)
Market Cap & Net Worth: Quince Therapeutics, Inc. (QNCX)
Quince Therapeutics, Inc. market cap. Quince Therapeutics, Inc. (NASDAQ:QNCX) has a market capitalization of $30.87 Million ($30.87 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #23478 globally and #5120 in its home market, demonstrating a 0.37% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Quince Therapeutics, Inc.'s stock price $32.95 by its total outstanding shares 1017063 (1.02 Million). Also see Quince Therapeutics, Inc. (QNCX) cash flow conversion for how efficiently the company converts equity into cash flow.
Quince Therapeutics, Inc. Market Cap History (2019–2026)
Quince Therapeutics, Inc. market cap history from 2019 to 2026. Data shows growth from $57.10 Million to $33.51 Million (0.02% CAGR). Check QNCX live share price for real-time trading data and today's change.
Index Memberships
Quince Therapeutics, Inc. is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.00% | #661 of 976 |
|
NASDAQ Composite
IXIC
|
$40.12 Trillion | 0.00% | #2195 of 3165 |
Weight: Quince Therapeutics, Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Quince Therapeutics, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Quince Therapeutics, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is Quince Therapeutics, Inc. growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of QNCX by Market Capitalization
Companies near Quince Therapeutics, Inc. in the global market cap rankings as of November 5, 2026. Also see Quince Therapeutics, Inc. total assets for a full breakdown of the balance sheet.
Key companies related to Quince Therapeutics, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Quince Therapeutics, Inc. (2019–2026)
Market capitalization of Quince Therapeutics, Inc. from 2019 to today. Between 2019 and today, Quince Therapeutics, Inc.'s market cap moved from $57.10 Million to $ 33.51 Million, with a yearly change of 0.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $33.51 Million | +883.58% |
| 2025 | $3.41 Million | +79.14% |
| 2024 | $1.90 Million | +78.10% |
| 2023 | $1.07 Million | +64.84% |
| 2022 | $647.87K | -94.95% |
| 2021 | $12.84 Million | -54.57% |
| 2020 | $28.25 Million | -50.52% |
| 2019 | $57.10 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Quince Therapeutics, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $30.87 Million USD |
| MoneyControl | $30.87 Million USD |
| MarketWatch | $30.87 Million USD |
| marketcap.company | $30.87 Million USD |
| Reuters | $30.87 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Quince Therapeutics, Inc.
Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disord… Read more